Form 8-K · Current report
Kenvue 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0001944048
- Accession no.
- 0001944048-26-000141
Summary
Kenvue reported second-quarter 2026 net sales up 3.0% and organic sales up 1.6%, its third consecutive quarter of net and organic sales growth, with diluted EPS of $0.24 and adjusted diluted EPS of $0.31, and said it will not give forward-looking guidance or hold a conference call because of its pending acquisition by Kimberly-Clark. Kenvue also said the FDA approved Tylenol with Naproxen, described as the first over-the-counter fixed-dose combination of acetaminophen and naproxen sodium, and said it expects the Kimberly-Clark transaction to close in the fourth quarter of 2026 subject to foreign regulatory approvals.
Key points
- Second-quarter 2026 net sales rose 3.0% year over year, including 1.6% organic growth and a 1.4% foreign currency benefit, with sales growth in all three segments.
- Gross profit margin was 58.2% versus 58.9% a year earlier, and operating income margin was 17.7% versus 18.0%, affected by inflation, tariffs and unfavorable transactional foreign exchange partly offset by supply chain productivity savings.
- The FDA approved Tylenol with Naproxen, supported by eight clinical studies and a three-year exclusivity period, with availability expected soon at major U.S. retailers.
- Kenvue shareholders and Kimberly-Clark shareholders approved the required proposals at special meetings on January 29, 2026, and the Hart-Scott-Rodino waiting period expired on February 4, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On August 6, 2026, Kenvue Inc. issued the attached press release (Exhibit 99.1) announcing its financial results for the fiscal second quarter ended June 28, 2026. The information contained under Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.